Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.
Szlosarek PW, Wimalasingham AG, Phillips MM, Hall PE, Chan PY, Conibear J, Lim L, Rashid S, Steele J, Wells P, Shiu CF, Kuo CL, Feng X, Johnston A, Bomalaski J, Ellis S, Grantham M, Sheaff M. Szlosarek PW, et al. Among authors: wimalasingham ag. Cancer Med. 2021 Oct;10(19):6642-6652. doi: 10.1002/cam4.4196. Epub 2021 Aug 12. Cancer Med. 2021. PMID: 34382365 Free PMC article. Clinical Trial.
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.
Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E, Bahl A, Fife K, Webb A, Crabb SJ, Geldart T, Hill R, Dunlop J, McLaren D, Ackerman C, Wimalasingham A, Beltran L, Nathan P, Powles T. Hall PE, et al. Eur Urol Focus. 2020 Sep 15;6(5):999-1005. doi: 10.1016/j.euf.2019.01.010. Epub 2019 Feb 6. Eur Urol Focus. 2020. PMID: 30738795 Clinical Trial.
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.
Powles T, Sarwar N, Stockdale A, Sarker SJ, Boleti E, Protheroe A, Jones R, Chowdhury S, Peters J, Oades G, O'Brien T, Sullivan M, Aitchison M, Beltran L, Worth D, Smith K, Michel C, Trevisan G, Harvey-Jones E, Wimalasingham A, Sahdev A, Ackerman C, Crabb S. Powles T, et al. JAMA Oncol. 2016 Oct 1;2(10):1303-1309. doi: 10.1001/jamaoncol.2016.1197. JAMA Oncol. 2016. PMID: 27254750 Clinical Trial.
Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
de Bruijn R, Wimalasingham A, Szabados B, Stewart GD, Welsh SJ, Kuusk T, Blank C, Haanen J, Klatte T, Staehler M, Powles T, Bex A. de Bruijn R, et al. Eur Urol Oncol. 2020 Apr;3(2):168-173. doi: 10.1016/j.euo.2019.12.004. Epub 2020 Jan 16. Eur Urol Oncol. 2020. PMID: 31956080
Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.
Rose TL, Deal AM, Ladoire S, Créhange G, Galsky MD, Rosenberg JE, Bellmunt J, Wimalasingham A, Wong YN, Harshman LC, Chowdhury S, Niegisch G, Liontos M, Yu EY, Pal SK, Chen RC, Wang AZ, Nielsen ME, Smith AB, Milowsky MI; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Rose TL, et al. Bladder Cancer. 2016 Oct 27;2(4):405-413. doi: 10.3233/BLC-160072. Bladder Cancer. 2016. PMID: 28035321 Free PMC article.
The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
Davies CR, Guo T, Burke E, Stankiewicz E, Xu L, Mao X, Scandura G, Rajan P, Tipples K, Alifrangis C, Wimalasingham AG, Galazi M, Crusz S, Powles T, Grey A, Oliver T, Kudahetti S, Shaw G, Berney D, Shamash J, Lu YJ. Davies CR, et al. Among authors: wimalasingham ag. Front Oncol. 2023 Jan 16;12:1060864. doi: 10.3389/fonc.2022.1060864. eCollection 2022. Front Oncol. 2023. PMID: 36727071 Free PMC article.